CN114432489A - 在金属表面制备具有长效抗菌效果多肽涂层的方法 - Google Patents
在金属表面制备具有长效抗菌效果多肽涂层的方法 Download PDFInfo
- Publication number
- CN114432489A CN114432489A CN202210115321.0A CN202210115321A CN114432489A CN 114432489 A CN114432489 A CN 114432489A CN 202210115321 A CN202210115321 A CN 202210115321A CN 114432489 A CN114432489 A CN 114432489A
- Authority
- CN
- China
- Prior art keywords
- coating
- metal
- polypeptide
- antibacterial effect
- magnesium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000576 coating method Methods 0.000 title claims abstract description 134
- 239000011248 coating agent Substances 0.000 title claims abstract description 124
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 87
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 85
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 85
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 76
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 69
- 239000002184 metal Substances 0.000 title claims abstract description 69
- 238000000034 method Methods 0.000 title claims abstract description 44
- 239000004814 polyurethane Substances 0.000 claims abstract description 47
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229920002635 polyurethane Polymers 0.000 claims abstract description 34
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 30
- 239000011777 magnesium Substances 0.000 claims abstract description 30
- 239000004632 polycaprolactone Substances 0.000 claims abstract description 28
- 229920001610 polycaprolactone Polymers 0.000 claims abstract description 28
- 239000000243 solution Substances 0.000 claims abstract description 24
- 238000002156 mixing Methods 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000011259 mixed solution Substances 0.000 claims abstract description 9
- 239000002245 particle Substances 0.000 claims abstract description 8
- 238000005498 polishing Methods 0.000 claims abstract description 8
- 239000011247 coating layer Substances 0.000 claims abstract description 5
- 230000002779 inactivation Effects 0.000 claims abstract description 5
- 229910000861 Mg alloy Inorganic materials 0.000 claims description 43
- 239000010410 layer Substances 0.000 claims description 16
- 150000002739 metals Chemical class 0.000 claims description 11
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 claims description 8
- 229910010271 silicon carbide Inorganic materials 0.000 claims description 8
- 238000004140 cleaning Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000003517 fume Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000012620 biological material Substances 0.000 abstract description 7
- 239000007857 degradation product Substances 0.000 abstract description 6
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 5
- 238000005265 energy consumption Methods 0.000 abstract description 3
- 238000003912 environmental pollution Methods 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 3
- 231100000956 nontoxicity Toxicity 0.000 abstract description 3
- 238000004506 ultrasonic cleaning Methods 0.000 abstract description 3
- DISRGUXSEDBDDN-OAHLLOKOSA-N 6-[6-(methoxymethyl)pyridin-3-yl]-4-[[(1R)-1-(oxan-4-yl)ethyl]amino]quinoline-3-carboxamide Chemical compound COCC1=CC=C(C=N1)C=1C=C2C(=C(C=NC2=CC=1)C(=O)N)N[C@H](C)C1CCOCC1 DISRGUXSEDBDDN-OAHLLOKOSA-N 0.000 description 27
- 238000012650 click reaction Methods 0.000 description 21
- 230000000845 anti-microbial effect Effects 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- 239000000956 alloy Substances 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 15
- 229910045601 alloy Inorganic materials 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 9
- 229910001069 Ti alloy Inorganic materials 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000002238 attenuated effect Effects 0.000 description 7
- 230000003385 bacteriostatic effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 238000002149 energy-dispersive X-ray emission spectroscopy Methods 0.000 description 6
- 238000000053 physical method Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 230000007797 corrosion Effects 0.000 description 5
- 238000005260 corrosion Methods 0.000 description 5
- 239000007769 metal material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000000316 bone substitute Substances 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 3
- 239000002861 polymer material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 229910001868 water Inorganic materials 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 229910052785 arsenic Inorganic materials 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 2
- NDIURPSCHWTXDC-UHFFFAOYSA-N 2-(4,5-dimethoxy-2-nitrophenyl)acetohydrazide Chemical compound COC1=CC(CC(=O)NN)=C([N+]([O-])=O)C=C1OC NDIURPSCHWTXDC-UHFFFAOYSA-N 0.000 description 1
- 208000005223 Alkalosis Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- -1 Pure Magnesium (PM) Chemical class 0.000 description 1
- 241001336827 Rana chensinensis Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002340 alkalosis Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000007750 congenital bile acid synthesis defect Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910001234 light alloy Inorganic materials 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000006994 mh medium Substances 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 229960005264 piperacillin sodium Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 239000011527 polyurethane coating Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960000373 tazobactam sodium Drugs 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/06—Titanium or titanium alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/047—Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D7/00—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials
- B05D7/14—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials to metal, e.g. car bodies
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D167/00—Coating compositions based on polyesters obtained by reactions forming a carboxylic ester link in the main chain; Coating compositions based on derivatives of such polymers
- C09D167/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D175/00—Coating compositions based on polyureas or polyurethanes; Coating compositions based on derivatives of such polymers
- C09D175/04—Polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D189/00—Coating compositions based on proteins; Coating compositions based on derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
- C09D5/14—Paints containing biocides, e.g. fungicides, insecticides or pesticides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/06—Coatings containing a mixture of two or more compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D2202/00—Metallic substrate
- B05D2202/20—Metallic substrate based on light metals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D2508/00—Polyesters
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Animal Behavior & Ethology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种在金属表面制备具有长效抗菌效果多肽涂层的方法,包含以下步骤包含以下步骤:(1)金属预处理:(a)将金属抛光;(b)80%乙醇中室温超声波清洗5分钟;(c)紫外线灭活处理;(2)多肽涂层的制备:(a)将聚己内酯/聚氨酯颗粒与氯仿溶液,按照3%W/V的比例混合;(b)多肽F3加入经步骤(a)制得的溶液,形成同质混合溶液;(c)将经步骤(1)处理过的金属浸入同质混合溶液中,通风2‑4小时,在金属表面形成多肽包覆层。该方法制备的镁基生物材料具有稳定、长效的良好抗菌消炎功能。该涂层具有良好的生物兼容性、安全性,且降解产物不具备毒性。制备方法简单易行、成本低、能耗小、无环境污染、容易规模化生产。
Description
技术领域
本发明涉及金属材料制造,确切地说是一种在金属表面制备具有长效抗菌效果多肽涂层的方法。
背景技术
随着人类社会的的发展和人类活动的增加,人类骨组织和硬组织的损伤越来越频繁,因此对相应的骨组织固定、修复及替代生物材料的需求越来越多,要求越来越高。传统的骨固定和替代材料如钛合金及不锈钢等金属材料,由于与人体骨组织的弹性模量相差很大,与人骨的力学性能相差很大,一旦植入体内容易产生很多问题:应力遮挡、由于金属离子的释放造成局部PH值变化从而造成居中感染或炎性反应。因而生物相容性差,很难适应骨愈合过程。而高分子材料由于力学性能查尤其是塑性、韧性及径向力学性能很差,所以很难作为骨替代材料而广泛应用。
作为一种典型的轻合金,镁合金与人骨就有几乎相同的弹性模量,所以与人骨力学性能很接近,是个理想的人骨替代材料。另外镁是人体新陈代谢和生物反应所必须的成分,镁通过与称骨细胞的结合,对于骨的生长及强化均有很好的促进作用。镁作为骨替代材料具有很好的生物兼容性。
然而由于镁化学性质很活泼,在人体内环境内由于多种离子的存在,使得镁和镁合金移植材料降解速率很快,进而使得局部体液环境PH值明显增高,从而可能引发碱中毒,从而造成局部炎性反应,使得细胞死亡。因而控制镁及其合金在体内的降解速率成为镁合金作为骨移植材料应用的关键问题。
另外镁合金作为体内和体外的替代材料时,由于不具备明显的抑菌、消炎作用,容易在体内、体外引起细菌增生,并会造成额外的炎症反应。这进一步限制了镁合金的广泛应用。
为了解决镁合金在体内降解过快的问题,许多方法被用来改善镁的耐腐蚀性能,常见的方法有对表面利用各种物理和化学方法进行强化。目前为了使材料更具有生物活性、生物兼容性,生成各种具有生物功能性涂层;然而由于镁合金自身材料的缺陷使得材料表面涂层的功能性下降,所具有的活性下降,影响材料的使用。而且现有的生物功能性涂层在提高材料耐腐蚀性能的同时很难兼顾抑菌和抗炎作用。因此目前急需制备一种既能提高镁合金耐腐蚀性能,同时具有抗炎抑菌做的生物功能涂层。
CN 111494704 A公开了一种制备小肽涂层的镁基合金生物材料的方法及其应用,将镁基合金分别经过超声波清洗去除镁基合金AZ31表面的杂质,利用氯仿将聚氨酯进行溶解,然后将处理过的镁基合金AZ31放入溶解有聚氨酯的氯仿液,使镁基合金AZ31完全包覆在溶液内,取出镁基合金AZ31,静置直至其表面的溶液固化,然后在等离子反应器里利用点击反应使镁基合金AZ31表面包覆的聚氨酯活化,最后将表面活化的聚氨酯包覆镁基合金AZ31 放入溶解有多肽的磷酸钠溶液进行震荡,使二者充分反应,以形成相应的多肽涂层。本发明形成稳定的生物包覆涂层,改善了镁合金的抑菌性能及耐腐蚀性能,小肽涂层的镁基合金生物材料具有良好的生物活性和人体兼容性,应用于制备硬组织缺损修复材料。
上述方法的存在的问题或缺点是:
(1)其所选的高分子生物材料为聚氨酯;
(2)其是利用化学点击方应的方法生成涂层的,即在金属表面利用等离子点击反应生使得包覆金属表面的聚氨酯层获得功能团(如过氧基团和羟基等),从而活化,能够跟多肽结合,从而在聚氨酯表面生成一层多肽涂层。该涂层里的多肽仅存在于聚氨酯的表面。
(3)化学点击反应生成涂层(聚氨酯)的代谢/降解产物为二氧化碳、水和氨气。
(4)点击反应生成的涂层有效抗菌效果仅能维持96小时(四天)左右。最大的抗菌效果在24小时时,为有效抑菌面积约为380mm2,而在96小时候抗菌效果急剧衰减到70mm2以下。
(5)涂层抗菌效果是由多肽的释放过程决定的;点击反应涂层多肽的缓释,仅为表面一层的缓释,由于表面所结合的多肽量有限,所以缓释过程是持续大幅度衰减的。因此抗菌时间也较短。抗菌效果也是持续大幅衰减。
本研究涉及金属料科学技术领域,尤其涉及通过一种便捷的物理方法将一种提取自澳洲树蛙的多肽制成涂层包覆于镁合金表面的制备方法。该方法制备的镁基生物材料经实验证实具有稳定、长效的良好抗菌消炎功能。该涂层具有良好的生物兼容性、安全性,且降解产物不具备毒性。制备方法简单易行、成本低、能耗小、无环境污染、容易规模化生产。
发明内容
本发明要解决的技术问题是提供一种在金属表面制备具有长效抗菌效果多肽涂层的方法,该方法制备的镁基生物材料经实验证实具有稳定、长效的良好抗菌消炎功能。该涂层具有良好的生物兼容性、安全性,且降解产物不具备毒性。制备方法简单易行、成本低、能耗小、无环境污染、容易规模化生产。
为解决上述技术问题,本发明采用如下技术手段:
一种在金属表面制备具有长效抗菌效果多肽涂层的方法,所述的金属为镁、冷拔镁合金及退火镁合金中的任意一种,包含以下步骤:
(1)金属预处理:
(a)将金属用400目碳化硅纸抛光1-3分钟以去除原始氧化层,然后用800-2400目碳化硅纸抛光2-5分钟以改善样品表面质量并获得均匀的粗糙度;将金属旋转90度进行研磨、抛光,去除先前产生的划痕;
(b)将金属分别放入80%乙醇中室温超声波清洗5分钟;
(c)在制备涂层之前,金属用紫外线灯照射30分钟灭活处理;
(2)多肽涂层的制备:
(a)选用聚己内酯和聚氨酯,作为将金属表面的包覆剂,将固态白色聚己内酯/聚氨酯颗粒与无色透明氯仿溶液,氯仿溶液纯度大于或等于99.5%,颗粒与氯仿溶液按照3%W/V的比例混合并在室温下进行振荡搅拌;
(b)然后将合成的纯度大于95%的多肽F3加入经步骤(a)制得的溶液,然后在室温下,利用高速离心器进行震荡搅拌约1-3个小时直至形成同质混合溶液;
(c)将经步骤(1)处理过的金属浸入经过无菌化处理的同质混合溶液中;将浸泡后的金属置于通风橱中2-4小时,使氯仿迅速挥发从而在金属表面形成一层均匀、紧密而稳定的聚氨酯/聚己内酯的包覆层。
进一步的优选技术方案如下:
所述的照射的时长为30分钟。
本方法的优点在于:
(1)本发明是通过物理结合的方法生成涂层,所用的高分子生物材料主要为聚己内酯。
(2)利用物理混合方法生成的多肽涂层是均匀分布整个的高分子材料层(主要是聚己内酯)内,从表面到内部、底部。
(3)物理结合生成涂层的代谢/降解产物为二氧化碳和水。二者相比,物理结合涂层更具有生物兼容性、更安全。
(4)物理结合涂层无论是在抗菌时间和抗菌效果明显大大由于点击反应涂层。物理结合涂层的最大抗菌效果在24小时,无论是加涂层后的镁合金还是加涂层钛合金的有效抑菌面积都大于550mm2。而物理结合涂层有效抗菌时间也远远长于点击反应涂层:其中加涂层后的钛合金的抗菌效果可以持续到7天(图8A);而加涂层后的镁合金的抗菌时间也达到了了6天。
(5)涂层抗菌效果是由多肽的释放过程决定的。物理结合涂层,多肽的缓释是从上到下进行的,随着上层的多肽释放掉,邻近层的多肽进行补充,形成了按照多肽浓度梯度进行补充型缓释。所以物理结合涂层中的多肽缓释是逐步进行的,故而抗菌效果也是逐步衰减的。故而抗菌效果持续时间更长,效果更好。加涂层后的钛合金更是出现了一个从72小时到144 小时的抗菌效果稳定区。再有就是物理结合涂层所含有的多肽量要大大高于点击反应涂层所含的多肽量。物理结合的专利比点击方应专利的有效抗菌时间提高了近80%,达到了7天左右,这可以有效的抑制移植物移植后近一周的急性感染期和炎性期反应。另外,最大抗菌效果也提高了近50%。所以相比较而言,物理结合方法制备涂层,具有更快、更好的应用前景。
(6)物理结合方法生成涂层跟简单,便于操作,对环境污染更少,成本更低,因而更容易规模化批量生产。
附图说明
图1是本发明的金属的微观组织图,其中,图A为纯镁金属;图B为冷拔金属AZ31;图C退火金属AZ31。
图2是聚己内酯的结构图。
图3是本发明的物理方法形成的多肽+聚己内酯/聚氨酯涂层示意图。
图4是不同金属包覆同种涂层时抗菌效果的分析,其中,图A是PC+F3涂层;图B是PU+F3涂层。
图5是同种金属包覆不同种涂层时抗菌效果的分析,其中,图A是冷拔AZ31;图B图B纯镁;图C是退火AZ31。
图6是扫描电镜SEM与能谱分析EDS图,其中,图A为PC+F3涂层;图B为PU+F3 涂层;图C为不同金属的PC+F3涂层的EDS分析;图D为不同金属的PU+F3涂层的EDS 分析。
图7是点击反应生成多肽涂层与物理混合生成多肽涂层的原理比较与分析图。
图8是点击反应生成多肽涂层与物理混合生成多肽涂层的体外抗菌效果比较及多肽缓释模型分析图。
图9是体内抗菌效果实验图。
图10是物理混合涂层包覆镁合金抑制体内72小时后,移植部位组织研磨稀释后体外抗菌实验结果图。
具体实施方式
下面结合实施例,进一步说明本发明。
参见图1-图3可知,本发明的一种在金属表面制备具有长效抗菌效果多肽涂层的方法,所述的金属为镁、冷拔镁合金及退火镁合金中的任意一种,包含以下步骤:
(1)金属预处理:
(a)将金属用400目碳化硅纸抛光1-3分钟以去除原始氧化层,然后用800-2400目碳化硅纸抛光2-5分钟以改善样品表面质量并获得均匀的粗糙度;将金属旋转90度进行研磨、抛光,去除先前产生的划痕;
(b)将金属分别放入80%乙醇中室温超声波清洗5分钟;
(c)在制备涂层之前,金属用紫外线灯照射30分钟灭活处理;
(2)多肽涂层的制备:
(a)选用聚己内酯和聚氨酯,作为将金属表面的包覆剂,将固态白色聚己内酯/聚氨酯颗粒与无色透明氯仿溶液,氯仿溶液纯度大于或等于99.5%,颗粒与氯仿溶液按照3%W/V的比例混合并在室温下进行振荡搅拌;
(b)然后将合成的纯度大于95%的多肽F3加入经步骤(a)制得的溶液,然后在室温下,利用高速离心器进行震荡搅拌约1-3个小时直至形成同质混合溶液;
(c)将经步骤(1)处理过的金属浸入经过无菌化处理的同质混合溶液中;将浸泡后的金属置于通风橱中2-4小时,使氯仿迅速挥发从而在金属表面形成一层均匀、紧密而稳定的聚氨酯/聚己内酯的包覆层。
所述的照射的时长为30分钟。
实验及性能测试
(一)金属试样的制备
金属试样,金属包括纯镁(Pure magnesium,PM)、冷拔镁合金AZ31(Cold extrudedAZ31, CE AZ31)以及退火镁合金AZ31(Fully annealed AZ31,FAAZ31)。所有三种镁合金都是直径为 5.0mm的棒材。FA AZ31样品经过完全再结晶退火热处理。在惰性气体气氛(氩气)中将它们加热到330-350℃,保持3-5小时,然后在炉中冷却。所有的试样被加工成厚度为2mm 的小圆饼(直径为5mm)。三种镁合金试样的平均晶粒尺寸为:纯镁的平均晶粒尺寸为22μ m,冷拔AZ31合金的平均晶粒尺寸为18.2μm,退火AZ31合金的平均晶粒尺寸为15.9 μm。硬度测试结果为:冷拔AZ31的布氏硬度为79HV;退火AZ31的布氏硬度为67.1;而纯镁的布氏硬度为42.8HV。
试件样品用400目碳化硅纸抛光1-3分钟以去除原始氧化层,然后用800-2400目碳化硅纸抛光2-5分钟以改善样品表面质量并获得均匀的粗糙度。将所有金属样品旋转90度,以确保下一步的研磨和抛光去除先前产生的划痕。然后将金属样品分别放入80%乙醇中室温超声波清洗5分钟。在制备涂层之前,所有的样品材料都经过灭活处理:用紫外线灯照射30 分钟。
(二)涂层制备
(a)选用聚己内酯和SelectophoreTM生产的聚氨酯(等级MQ100)作为将金属表面的包覆剂,首先将固态白色聚己内酯/聚氨酯颗粒与无色透明氯仿溶液(纯度≥99.5%)按照3% (W/V)的比例混合并在室温下进行振荡搅拌。
(b)然后将合成的高纯度(>95%)多肽F3加入搅拌均匀的氯仿聚和己内酯/聚氨酯的溶液,然后在室温下,利用高速离心器进行震荡搅拌约1-3个小时直至形成同质混合溶液。
(c)将超声波表面处理过的三种镁基合金试样(矮圆柱状,直径为5mm,厚度为2mm)放入经过无菌化处理的玻璃器皿里。
(d)将三种金属试样浸于200μL的多肽+氯仿+聚氨酯/聚己内酯溶液中,将均匀包覆聚氨酯/聚己内酯的三种镁合金材料及玻璃器皿置于通风橱中2-4小时,使氯仿迅速挥发从而在金属表面形成一层均匀、紧密而稳定的聚氨酯/聚已内酯的包覆层。
(三)抑菌对比实验
抑菌对比实验具体操作如下:
(a)抑菌试验的试样都制备成制成直径为统一制成直径为5mm,厚度为2mm的小尺寸镁片,尺寸公差为0.002mm;
(b)将原始的三种不同处理态的镁合金AZ31(CE AZ31,FAAZ31,PM)经过物理方法分别于与聚氨酯和聚己内酯形成聚氨酯+F3和聚己内酯+F3的多肽涂层。将包覆涂层的三种镁合金试样进行表面清洗:利用纯净水进行清洗,在超声波清洗器里清洗3-5分钟,以去除表面的杂质和黏着物;
(c)将清洗后的各种试样放入抑菌实验皿在37度的恒温孵化箱进行耐药性金黄色葡萄球菌的168小时的抑菌试验。
(d)收集对数期生长耐甲氧西林的金黄色葡萄球菌(MRSA,GDM1.1263),MH培养基调整菌悬液浓度为2.0×105CFU/ml。用无菌棉拭子蘸取菌液,管壁旋转挤压几次,去掉过多的菌液。用拭子均匀涂布整个M-H药敏琼脂平板(广州远明生物)。药敏纸片(OXOID,美国)分别加入20ug的F3多肽,将纸片贴到M-H琼脂平板上,平板倒放,37℃孵育,培养过夜。20ug哌拉西林钠他唑巴坦钠(Tazocin)与空白的药敏片(BASD)以及原始的两种状态的AZ31镁合金作为对照。游标卡尺测量抑菌圈大小。
其结果如下表所示:
表一、物理结合多肽涂层体外抑菌试验结果(抑菌圈直径)
为了更有效的对比不同样品的抗菌性能,我们引入了抑菌环的有效抑菌面积这个量来衡量抗菌能力的大小。具体的计算可以参照以下的公式:
Ae=At-As (1)
其中,Ae为抑菌环有效面积,At和As分别为总面积和样品原始面积。At和As可以通过以下公式得到:
As=πrs2 (2)
At=πrt2 (3)
其中,rs为样品的原始直径,rt为包括抑菌环有效面积和样品原始面积的总直径(即为实验所测得结果的平均值)。
从图4中的图A部分和表一可以看出,对于聚己内酯PC+F3多肽的涂层来看,包覆了该种涂层的退火合金AZ31和纯镁具有最好的体外抗菌效果,而且抗菌效果可以持续到6-7天 (144-168小时之间);且这两者的抗菌能力相差不多,退火镁合金稍好一些。而冷拔的AZ31 包覆同种涂层后的体外抗菌效果只维持了4-5天(96-120小时之间)。而且抗菌的能力明显低于前两者。图4中的图B和表一可以看出,对于聚氨酯PU+F3多肽涂层来看,包覆该涂层的纯镁具有更为显著的抗菌效果(这与之前的研究结果有些差异,分析原因为包覆的涂层要多一些)。而退火镁合金AZ31与冷拔镁合金AZ31包覆PU+F3涂层后,具有相近的抗菌效果。三种金属材料包覆PU+F3涂层后的抗菌效果可以维持96-120小时,约4-5天时间。
图5比较了同种金属包覆不同种涂层时抗菌效果的差异:除了冷拔的AZ31之外,其余的两种金属(纯镁和退火AZ31)的PC+F3涂层的有效抗菌时间均比PU+F3的延长了2天(48小时)左右。而且对于三种金属来说,与PU+F3相比,PC+F3涂层的抗菌能力均有明显的提高,以退火AZ31最为显著:有效抑菌面积从PU+F3的300mm2增加到PC+F3的560mm2,增加了近一倍。
综上所述,三种金属的PC+F3涂层与PU+F3涂层均有长时间的抗菌能力。PC+F3涂层的抗菌能力和抗菌时间相比较于PU+F3涂层更好一些。
(四)扫描电镜SEM与能谱分析EDS
使用能量色散X射线光谱(EDS)结合扫描电子显微镜JEOL 6010 SEM分析了三种金属材料包覆的两种涂层的表面形貌及元素成分组成。
从图6中的图A和图B可以看出,PC+F3涂层表面布满了明显的颗粒状结构,表面起伏明显;而PU+F3涂层表面比较平坦,起伏不大。结合图6的结果来看,这种起伏状的表面致密结构增加了多肽与表面的接触面积,显著增加表面附着的多肽量,从而显著提高材料的抗菌能力。
另外这种起伏的结构(相对多肽而言的大尺度空洞,是多肽陷于其中)可以一定程度上使得多肽被束缚在某些区域,从而在于细菌接触时,呈一种结构性的梯度缓释,从而造成了抗菌效果的延长。
另外从图6中的图C和图D来看,两种涂层包覆三种不同镁合金材料时,其表面的成分没有明显的差别。故而可以看出三种材料的PU+F3和PC+F3涂层都是均匀的。故而这种通过物理结合制备涂层的方法是稳定的、可行的,不会造成涂层成分的明显波动。
总之,利用这种物理方法制备的涂层是可行的有效的。尤其是PC+F3的涂层抗菌效果更加明显,持续时间更长,同时降解产物仅为二氧化碳和水,都是对人体无害且可以吸收的。
参见图7,点击反应生成多肽涂层与物理混合生成多肽涂层的原理比较与分析,其中图A 点击反应方法生成涂层的原理;图B物理结合方法生成涂层的原理。
利用化学点击方应的方法生成涂层的,即在金属表面利用等离子点击反应生使得包覆金属表面的聚氨酯层获得功能团(如过氧基团和羟基等),从而活化,能够跟多肽结合,从而在聚氨酯表面生成一层多肽涂层。该涂层里的多肽仅存在于聚氨酯的表面。
利用有目的设计的特定物理混合方法生成的多肽涂层是均匀分布整个的高分子材料层聚己内酯内,从表面到内部、底部。
参见图8,点击反应生成多肽涂层与物理混合生成多肽涂层的体外抗菌效果比较及多肽缓释模型分析图。
点击反应生成多肽涂层与物理混合生成多肽涂层的体外抗菌效果比较及多肽缓释模型分析:图A物理方法生成的聚己内酯和F3多肽涂层包覆的钛合金的体外抗菌实验;图B物理方法生成的包覆有聚己内酯和F3多肽涂层的镁合金的体外抗菌实验;图C点击方应方法生成的聚氨酯和F3多肽涂层包覆的镁合金的体外抗菌实验;图D物理结合生成涂层的多肽缓释过程;图E点击方应生成涂层的多肽缓释过程。
两种方法生成的涂层的抗菌效果及持续时间有很的差异:点击反应生成的涂层有效抗菌效果仅能维持96小时(四天)左右,如图C所示。最大的抗菌效果在24小时时,为有效抑菌面积约为380mm2,而在96小时候抗菌效果急剧衰减到70mm2以下。而物理结合涂层无论是在抗菌时间和抗菌效果明显大大由于点击反应涂层。物理结合涂层的最大抗菌效果在24小时,无论是加涂层后的镁合金还是加涂层钛合金的有效抑菌面积都大于550mm2,如图A、C所示。而物理结合涂层有效抗菌时间也远远长于点击反应涂层:其中加涂层后的钛合金的抗菌效果可以持续到7天(图A);而加涂层后的镁合金的抗菌时间也达到了了6天(图C)。
再有就是涂层抗菌效果是由多肽的释放过程决定的。然而两种涂层的多肽缓释过程是截然不同的。物理结合涂层,多肽的缓释是从上到下进行的(图D),随着上层的多肽释放掉,邻近层的多肽进行补充,形成了按照多肽浓度梯度进行补充型缓释。所以物理结合涂层中的多肽缓释是逐步进行的,故而抗菌效果也是逐步衰减的。故而抗菌效果持续时间更长,效果更好。加涂层后的钛合金更是出现了一个从72小时到144小时的抗菌效果稳定区。再有就是物理结合涂层所含有的多肽量要大大高于点击反应涂层所含的多肽量。
而点击反应涂层多肽的缓释,仅为表面一层的缓释,由于表面所结合的多肽量有限,所以缓释过程是持续大幅度衰减的。因此抗菌时间也较短。抗菌效果也是持续大幅衰减。
总之物理结合的专利比点击方应专利的有效抗菌时间提高了近80%,达到了7天左右,这可以有效的抑制移植物移植后近一周的急性感染期和炎性期反应。另外,最大抗菌效果也提高了近50%。所以相比较而言,物理结合方法制备涂层,具有更快、更好的应用前景。
图9体内抗菌效果实验图。
点击反应涂层没有移植在老鼠体内,进行体内抗菌实验研究。而物理结合涂层已移植入体内,进行体内观察和抗菌实验分析。具体操作是,将包覆有聚己内酯和F3多肽的镁合金一直在SD大鼠的胫骨周围72小时,在移植过程中同时滴入106CFU耐金黄色葡萄球菌。后取移植物周边的组织进行研磨并稀释不同倍数:10,100,103,104,105,106。然后将稀释成不同倍数的组织置于细菌培养皿中,并滴入同等量的耐金黄色葡萄球菌,室温培养24小时后观测。
通过对图9的分析,可以看出在移植体内72小时候,通过肉眼观测,移植物周围的组织没有发现明显的异常变化,也没有发现明显气泡产生,说明在此过程中7组材料都很稳定,没有发生腐蚀现象,没有发生炎性反应。
图10物理混合涂层包覆镁合金抑制体内72小时后,移植部位组织研磨稀释后体外抗菌实验结果图:A对照组;B 1E;C 2P;D 3A;E 1E+PC+F3;F 2P+PC+F3;G 3A+PC+F3。
结果表明,在抑制体内72小时候,包覆有聚己内酯和F3多肽涂层的金属在24小时后提取周围组织观察,具有明显的抗菌作用。三种为包覆涂层的纯金属比较来看,取自退火的AZ31 (3A)移植部位的组织相比较其他两种金周围的组织而言,具有更好的抗菌效果。相类似,通过物理方法包覆聚己内酯和F3多肽涂层的3A周围的组织也就有更好的抗菌效果。这说明在移植体内72小时后,涂层里的多肽进入到移植物周围的机体组织,从而使组织具有了显著的抗菌作用。故而包覆物理结合涂层的金属移植体内后,72小时仍然具有抗菌作用。这直接证明了,物理结合方法生成涂层的体内抗菌作用。
以上所述仅为本发明较佳可行的实施例而已,并非因此局限本发明的权利范围,凡运用本发明说明书及附图内容所作的等效结构变化,均包含于本发明的权利范围之内。
Claims (2)
1.一种在金属表面制备具有长效抗菌效果多肽涂层的方法,所述的金属为镁、冷拔镁合金及退火镁合金中的任意一种,其特征在于,包含以下步骤:
(1)金属预处理:
(a)将金属用400目碳化硅纸抛光1-3分钟以去除原始氧化层,然后用800-2400目碳化硅纸抛光2-5分钟以改善样品表面质量并获得均匀的粗糙度;将金属旋转90度进行研磨、抛光,去除先前产生的划痕;
(b)将金属分别放入80%乙醇中室温超声波清洗5分钟;
(c)在制备涂层之前,金属用紫外线灯照射30分钟灭活处理;
(2)多肽涂层的制备:
(a)选用聚己内酯和聚氨酯,作为将金属表面的包覆剂,将固态白色聚己内酯/聚氨酯颗粒与无色透明氯仿溶液,氯仿溶液纯度大于或等于99.5%,颗粒与氯仿溶液按照3%W/V的比例混合并在室温下进行振荡搅拌;
(b)然后将合成的纯度大于95%的多肽F3加入经步骤(a)制得的溶液,然后在室温下,利用高速离心器进行震荡搅拌约1-3个小时直至形成同质混合溶液;
(c)将经步骤(1)处理过的金属浸入经过无菌化处理的同质混合溶液中;将浸泡后的金属置于通风橱中2-4小时,使氯仿迅速挥发从而在金属表面形成一层均匀、紧密而稳定的聚氨酯/聚己内酯的包覆层。
2.根据权利要求1所述的在金属表面制备具有长效抗菌效果多肽涂层的方法,其特征在于:所述的照射的时长为30分钟。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210115321.0A CN114432489A (zh) | 2022-01-29 | 2022-01-29 | 在金属表面制备具有长效抗菌效果多肽涂层的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210115321.0A CN114432489A (zh) | 2022-01-29 | 2022-01-29 | 在金属表面制备具有长效抗菌效果多肽涂层的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114432489A true CN114432489A (zh) | 2022-05-06 |
Family
ID=81372110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210115321.0A Pending CN114432489A (zh) | 2022-01-29 | 2022-01-29 | 在金属表面制备具有长效抗菌效果多肽涂层的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114432489A (zh) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004045663A1 (en) * | 2002-11-20 | 2004-06-03 | Ethicon Gmbh | Surgical implant coated with a composition comprising a polyol fatty acid monoester |
CN1968719A (zh) * | 2004-06-16 | 2007-05-23 | 阿费内基有限公司 | 生物功能性涂层 |
US20070254006A1 (en) * | 2006-02-15 | 2007-11-01 | Massachusetts Institute Of Technology | Medical Devices and Coatings with Non-Leaching Antimicrobial Peptides |
CN101225604A (zh) * | 2008-02-03 | 2008-07-23 | 杭州万事利丝绸科技有限公司 | 一种含抗菌肽的涂层织物及其制备方法 |
CN101628133A (zh) * | 2009-08-11 | 2010-01-20 | 中国人民解放军第三军医大学第一附属医院 | 载缓释抗菌素涂层医用导管及其制备方法 |
CN102921049A (zh) * | 2012-09-28 | 2013-02-13 | 深圳清华大学研究院 | 抗菌医用导管及其制备方法 |
US20150224225A1 (en) * | 2012-09-12 | 2015-08-13 | Biocant- Centre De Invacao Em Biotechnologia | Antimicrobial coating compositions |
US20160166738A1 (en) * | 2014-12-11 | 2016-06-16 | Covidien Lp | Antimicrobial coatings for medical devices and processes for preparing such coatings |
CN111317865A (zh) * | 2018-12-17 | 2020-06-23 | 南京理工大学 | 双层抗菌复合薄膜的制备方法 |
CN111494704A (zh) * | 2020-04-14 | 2020-08-07 | 李贺杰 | 制备小肽涂层的镁基合金生物材料的方法及其应用 |
CN111588904A (zh) * | 2020-06-19 | 2020-08-28 | 浙江大学 | 含聚己内酯/聚维酮碘表层的载碘钛合金医用部件及其制作方法 |
WO2020214836A1 (en) * | 2019-04-16 | 2020-10-22 | Academia Sinica | Methods of coating antimicrobial peptides on the biomaterial and the biomaterial coated thereby |
-
2022
- 2022-01-29 CN CN202210115321.0A patent/CN114432489A/zh active Pending
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004045663A1 (en) * | 2002-11-20 | 2004-06-03 | Ethicon Gmbh | Surgical implant coated with a composition comprising a polyol fatty acid monoester |
CN1968719A (zh) * | 2004-06-16 | 2007-05-23 | 阿费内基有限公司 | 生物功能性涂层 |
US20070254006A1 (en) * | 2006-02-15 | 2007-11-01 | Massachusetts Institute Of Technology | Medical Devices and Coatings with Non-Leaching Antimicrobial Peptides |
CN101225604A (zh) * | 2008-02-03 | 2008-07-23 | 杭州万事利丝绸科技有限公司 | 一种含抗菌肽的涂层织物及其制备方法 |
CN101628133A (zh) * | 2009-08-11 | 2010-01-20 | 中国人民解放军第三军医大学第一附属医院 | 载缓释抗菌素涂层医用导管及其制备方法 |
US20150224225A1 (en) * | 2012-09-12 | 2015-08-13 | Biocant- Centre De Invacao Em Biotechnologia | Antimicrobial coating compositions |
CN102921049A (zh) * | 2012-09-28 | 2013-02-13 | 深圳清华大学研究院 | 抗菌医用导管及其制备方法 |
US20160166738A1 (en) * | 2014-12-11 | 2016-06-16 | Covidien Lp | Antimicrobial coatings for medical devices and processes for preparing such coatings |
CN106999631A (zh) * | 2014-12-11 | 2017-08-01 | 柯惠有限合伙公司 | 用于医疗器械的抗菌涂层和制备这种涂层的方法 |
CN111317865A (zh) * | 2018-12-17 | 2020-06-23 | 南京理工大学 | 双层抗菌复合薄膜的制备方法 |
WO2020214836A1 (en) * | 2019-04-16 | 2020-10-22 | Academia Sinica | Methods of coating antimicrobial peptides on the biomaterial and the biomaterial coated thereby |
CN111494704A (zh) * | 2020-04-14 | 2020-08-07 | 李贺杰 | 制备小肽涂层的镁基合金生物材料的方法及其应用 |
CN111588904A (zh) * | 2020-06-19 | 2020-08-28 | 浙江大学 | 含聚己内酯/聚维酮碘表层的载碘钛合金医用部件及其制作方法 |
Non-Patent Citations (5)
Title |
---|
ESTHER MARIE JIERONG LIN ET AL: ""Control Release Coating for Urinary Catheters with Enhanced Released Profile for Sustained Antimicrobial Protection"", 《ACS APPL. MATER. INTERFACES》 * |
KAIYANG LIM ET AL: ""Anhydrous polymer-based coating with sustainable controlled release functionality for facile, efficacious impregnation, and delivery of antimicrobial peptides"", 《BIOTECHNOLOGY AND BIOENGINEERIN》 * |
TIANFANG WANG ET AL: ""Mg alloy surface immobilised with caerin peptides acquires enhanced antibacterial ability and putatively improved corrosion resistance"", 《MATERIALS SCIENCE AND ENGINEERING: C》 * |
苗强等: ""一种经皮种植体抗菌肽控释涂层的构建及性能研究"", 《实用口腔医学杂志》 * |
赫荣智等: ""钛金属内植物表面抗菌肽的应用进展"", 《第二军医大学学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | The effects of laser shock peening on the mechanical properties and biomedical behavior of AZ31B magnesium alloy | |
Feng et al. | Fabrication and characterization of biodegradable Mg-Zn-Y-Nd-Ag alloy: Microstructure, mechanical properties, corrosion behavior and antibacterial activities | |
Maleki-Ghaleh et al. | Effect of surface modification by nitrogen ion implantation on the electrochemical and cellular behaviors of super-elastic NiTi shape memory alloy | |
Li et al. | Ultrahigh strength and uniform corrosion in Zn-Li alloys through ultrahigh pressure supersaturated solid solution treatment for biodegradable orthopedic applications | |
Zhang et al. | Tissue‐engineered bone functionalized with MoS2 nanosheets for enhanced repair of critical‐size bone defect in rats | |
Xiao et al. | Investigation of zinc-silver alloys as biodegradable metals for orthopedic applications | |
CN106606800B (zh) | 一种Zn-Fe系锌合金及其制备方法与应用 | |
Chen et al. | Enhanced mechanical, bio-corrosion, and antibacterial properties of Ti-Cu alloy by forming a gradient nanostructured surface layer | |
Zhang et al. | Fabrication, in vitro and in vivo properties of β-TCP/Zn composites | |
Xiong et al. | Using laser etched-array periodic structure surface to construct silver loaded titanium implants with combined efficient antibacterial and osteogenic properties | |
CN107829123B (zh) | 一种表面双层涂层的铝合金及其制备方法和应用 | |
Swain et al. | On the ion implantation synthesis of ag-embedded over sr-substituted hydroxyapatite on a nano-topography patterned ti for application in acetabular fracture sites | |
Behjat et al. | A novel titanium alloy for load-bearing biomedical implants: Evaluating the antibacterial and biocompatibility of Ti536 produced via electron beam powder bed fusion additive manufacturing process | |
Yu et al. | The osteogenesis performance of titanium modified via plasma-enhanced chemical vapor deposition: in vitro and in vivo studies | |
CN114086011B (zh) | 一种可控降解的成分梯度镁基植入材料的制备方法 | |
CN106637121A (zh) | 一种医用钛基金属材料及其制造方法 | |
CN111494704B (zh) | 制备小肽涂层的镁基合金生物材料的方法及其应用 | |
CN114432489A (zh) | 在金属表面制备具有长效抗菌效果多肽涂层的方法 | |
JP7507869B2 (ja) | マグネシウム合金の力学特性及び生物学的安定性を向上させる方法並びに材料を製造する方法及び使用 | |
CN110938812B (zh) | 一种具有抗菌性的表面改性镁合金及其制备方法与应用 | |
CN116815107A (zh) | 一种复合合金材料及其制备方法与应用 | |
CN111876707B (zh) | 一种具有促骨再生及抗菌双功能钛合金的改性方法及改性后的钛合金 | |
Zuo et al. | Enhancing the bioactivity and ductility of bulk metallic glass by introducing Fe to construct semi-degradable biomaterial | |
Li et al. | Preparation of HA-MAO coatings on β-type alloys and its corrosion resistance in high glucose environments | |
Qiu et al. | Improved mechanical and biological properties of Ti-13Nb-13Zr alloy treated by surface ultrasonic rolling and copper infiltration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |